Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: Implications for dose optimization

Cancer Research

Volumn 73, Issue 23, 2013, Pages 6865-6873

  Heidari, Pedram ^a   Wehrenberg Klee, Eric ^a   Habibollahi, Peiman ^a   Yokell, Daniel ^a   Kulke, Matthew ^b   Mahmood, Umar ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOTATOC GA 68; GALLIUM 68; KI 67 ANTIGEN; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESEARCH; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

EID: 84890280115     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1199     Document Type: Article

References (26)

1. KulkeMH, BensonAB III, BergslandE, BerlinJD, BlaszkowskyLS, ChotiMA, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012;10:724-64.
2. KulkeMH, BendellJ, KvolsL, PicusJ, PommierR, YaoJ. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011;4:29.
3. ReubiJC, KrenningE, LambertsSW, KvolsL. In vitro detection of somatostatin receptors in human tumors. Metabolism 1992;41:104-10.
4. PatelYC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-67.
5. FlorioT. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008;13:822-40.
6. RinkeA, MullerHH, Schade-BrittingerC, KloseKJ, BarthP, WiedM, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
7. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
8. 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011;52:1864-70.
9. 111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study withCT and MR imaging. QJM 1998;91:295-301.
10. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441-8.
11. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010;37:2004-10.
12. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
13. 68Ga-labelled peptides. Nucl Med Commun 2007;28:870-5.
14. 68Ga for medical application. J Nucl Med 2007;48:1741-8.
15. 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012;39:27-38.
16. 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med 2012;53:1829-35.
17. 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46:763-9.
18. PatlakCS, BlasbergRG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
19. PatlakCS, BlasbergRG, FenstermacherJD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
20. ChanJA, KulkeMH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011;12:136-48.
21. KulkeMH, AnthonyLB, BushnellDL, de HerderWW, GoldsmithSJ, KlimstraDS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52.
22. KulkeMH, SiuLL, TepperJE, FisherG, JaffeD, HallerDG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-43.
23. WaserB, TammaML, CescatoR, MaeckeHR, ReubiJC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009;50:936-41.
24. LevyAD, SobinLH. From the archives of the AFIP: Gastrointestinal carcinoids: imaging features with clinicopathologic comparison. Radiographics 2007;27:237-57.
25. ScarsbrookAF, GaneshanA, StathamJ, ThakkerRV, WeaverA, TalbotD, et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 2007;27:455-77.
26. 68)Ga- DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med 2011;52:1679-83.